OS Therapies Inc., a clinical-stage cancer immunotherapy company, has announced a partnership with EVERSANA for the U.S. commercialization of OST-HER2, a novel immunotherapy designed for recurrent, fully resected, pediatric lung metastatic osteosarcoma. This collaboration will leverage EVERSANA's extensive experience in the life sciences industry to ensure efficient market access and patient services for OST-HER2. With this partnership, OS Therapies aims to transform the treatment landscape for pediatric metastatic osteosarcoma, utilizing EVERSANA's integrated commercialization model to bring the innovation swiftly and effectively to healthcare providers and patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.